CANNAINVESTOR Magazine October / November 2016 - Page 81


Diverse Revenue Streams

SPI provides a diverse revenue stream. The Company currently generates revenue through providing database services to state governments for patient compliance and tax revenue reconciliation. Additionally, SPI continues to perform contract research for pharmaceutical and biotechnology firms. Aside from SOS Pain, SPI intends to launch eight additional products through the end of 2018, which will further accelerate revenue growth.

Experienced Management Team

The SPI team brings together extensive experience in big data analytics, traditional pharmaceutical testing and emphasis on quality control to develop superior dietary supplements. CEO Chris Meredith, the architect behind Helix, has built large databases and applications for Homeland Security and Lincare. James Baumgartner has over 23 years’ experience in drug discovery, development, and executive leadership. Dan Menard, the founder of SPIs contract research arm, is a CNS preclinical testing expert.

David Traylor

Golden Eagle Partners